Close Menu

cancer screening

The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.

Investigators reported on detection rates for cancers and precancers in a group of 350 individuals presenting for standard of care colonoscopy.

The company said the funds will support the continued development and commercialization of its genome-wide methylation assay for multi-cancer early detection.

The health system said that the program is encouraging patient compliance and increasing revenues and savings.

The approach, called Lung-CLiP, couples machine learning trained on epigenetic and clonal frequency data with the detection of alterations in blood-borne DNA.

The government payor is interested in public input on the evidence underlying the blood-based PCR test.

The Chinese company has also granted the underwriters of the offering an option to purchase an additional 200,004 ADS to cover overallotments.

Simulations suggested prostate cancer screening informed by polygenic risk scores is more cost effective and less prone to overdiagnoses than screening based on age alone.

Genetic testing results increasingly inform clinical decisions, though the inclusion of hereditary risk genes beyond BRCA1, BRCA2, and PALB2 sparked debate.

Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.